Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics to Present at Upcoming Investor Conferences
07:00am, Wednesday, 08'th May 2024
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
12:31pm, Tuesday, 07'th May 2024
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 06'th May 2024
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
09:31am, Friday, 03'rd May 2024
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
07:00am, Wednesday, 01'st May 2024
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
03:20pm, Tuesday, 30'th Apr 2024
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
11:06am, Monday, 29'th Apr 2024
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
01:17pm, Tuesday, 16'th Apr 2024
Intra-Cellular Therapies, Inc. achieved positive results from Study 501, using lumateperone as an adjunctive therapy for the treatment of patients with MDD; Both primary and secondary endpoints achiev
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
07:00am, Monday, 15'th Apr 2024
AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting ef
2 Under-the-Radar Growth Stocks to Consider
10:15am, Wednesday, 10'th Apr 2024
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
07:00am, Wednesday, 10'th Apr 2024
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
11:26am, Tuesday, 02'nd Apr 2024
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
07:00am, Monday, 01'st Apr 2024
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
07:44am, Wednesday, 27'th Mar 2024
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as di
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
12:26pm, Tuesday, 26'th Mar 2024
Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.
